Solid Tumors

Amplification of the MET gene is detected by fluorescence in situ hybridization (FISH).

disease state indication(s)
Non-Small Cell Lung Cancer (NSCLC)

clinical use
Predictive High level MET gene amplification can be found in 1-2% of NSCLC. MET gene amplification also determines eligibility for targeted therapies (such as crizotinib). When present in conjunction with an EGFR mutation, MET amplification may contribute to EGFR tyrosine kinase inhibitor (TKI) resistance.

methodology/product platform
Fluorescence in situ hybridization (FISH)

specimen type and requirements
Preferred: One (1) or two (2) formalin-fixed, paraffin-embedded (FFPE) blocks containing tumor tissue from the most recent surgery or biopsy.
Acceptable Alternative: Two (2) to three (3) unstained FFPE tissue sections recently cut at 4 µm thickness on glass slides, plus accompanying H&E stained slide.
Unacceptable: Specimens preserved in alternative (non-formalin) fixatives, decalcified specimens, fresh or frozen tissue.
Note: Use refrigerated cold pack for transport. Make sure cold pack is not in direct contact with specimen.

turnaround time
Tech-only (TC): 3 days
Global (TC & PC): 7 days

cpt code(s)
88377 (x1)

medicare moldx cpt code
Not applicable

regulatory classification
Laboratory developed test (LDT)

ordering option
Global (TC & PC) or Tech-only (TC)